LYCOS RETRIEVER 
Schering Laboratories
built 631 days ago
For Intron/Eulexin Products: Service Program, Schering Laboratories 2000 Galloping Hill Road Building K-5-2B2 Kenilworth, NJ 07033 Initial supply is for 3 months. Renewals available for 3 months at a time. Eulexin-Initial supply is for 6 months. Renewals available for 6 months at a time.
Source:
Schering Laboratories is the U.S. prescription pharmaceutical marketing arm of Schering-Plough Corporation (NYSE: SGP). Warrick Pharmaceuticals is the generic pharmaceutical marketing subsidiary of Schering-Plough, a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.
Source:
Sponsored by Schering/KEY, a marketing unit of Schering Laboratories, the "Will To Win" program will grant $35,000 in scholarships to 10 high school seniors who have become accomplished athletes despite the challenge of asthma. The top winner will receive a $10,000 Gold Award with four $5,000 Silver Awards and five $1000 Bronze Awards ... to be granted.
Source:
Richard W. Zahn, president, Schering Laboratories, stated, "The FDA's prompt action on this extended-dosing submission now provides physicians with the opportunity to develop optimal therapy for their hepatitis C patients. Patients who are diagnosed early and treated for a duration of 18-to-24 months have a better chance of maintaining a long-term response."
Source:
In the 1990s, Schering-Plough's largest and fastest-growing therapeutic category was in the area of asthma and allergy. Led by new product introductions, worldwide sales rose 24 percent in 1994 to approximately $1.46 billion. The most successful of these new drugs was Claritin (loratadine), a once-a-day, nonsedating antihistamine. Introduced in April 1993, Claritin was the third nonsedating antihistamine to reach the U.S. market. Despite its late arrival, in its first year on the market, Claritin had sales of nearly $200 million. It then captured the number one position in new prescriptions for plain antihistamines in less than a year and a half on the U.S. market, making it the largest single product for the company.
Source:
In January 2000, a top executive said Schering-Plough had resolved all the FDA's manufacturing issues. It hadn't. More than a year later, the company disclosed that regulators were refusing to approve Clarinex until it fixed its manufacturing problems.
Source:
MORE ABOUT
Schering Laboratories